Provided by Tiger Fintech (Singapore) Pte. Ltd.

Medtronic PLC

92.33
+0.82000.90%
Post-market: 92.330.00000.00%19:58 EDT
Volume:6.74M
Turnover:622.26M
Market Cap:118.42B
PE:28.23
High:92.74
Open:91.77
Low:91.56
Close:91.51
Loading ...

Company Profile

Company Name:
Medtronic PLC
Exchange:
NYSE
Establishment Date:
1949
Employees:
95000
Office Location:
Building Two,Parkmore Business Park West,Galway,Co. Galway,Ireland
Zip Code:
- -
Fax:
- -
Introduction:
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.

Directors

Name
Position
Geoffrey S. Martha
Chairman and Chief Executive Officer
Craig Arnold
Lead Independent Director
Andrea J. Goldsmith
Director
Elizabeth G. Nabel
Director
Gregory P. Lewis
Director
Kendall J. Powell
Director
Kevin E. Lofton
Director
Lidia Fonseca
Director
Randall J. Hogan, III
Director
Scott C. Donnelly
Director

Shareholders

Name
Position
Geoffrey S. Martha
Chairman and Chief Executive Officer
Karen L. Parkhill
Executive Vice President and Chief Financial Officer
Thierry Pieton
Executive Vice President and Chief Financial Officer
Brett Wall
Executive Vice President and President, Neuroscience Portfolio
Gregory L. Smith
Executive Vice President, Global Operations and Supply Chain
Ivan K. Fong
Executive Vice President, General Counsel and Corporate Secretary
Michael Marinaro
Executive Vice President and President, Medical Surgical Portfolio and Surgical Operating Unit
Robert ten Hoedt
Executive Vice President and President, Global Regions
Sean Salmon
Executive Vice President and President, Cardiovascular Portfolio